The purpose of this study was to evaluate the optimal renoprotective effect of ultrahigh doses of lisinopril, as reflected by short-term changes in urinary albumin excretion rate (UAER), in type 1 diabetic patients with diabetic nephropathy.At the Steno Diabetes Center, 49 type 1 diabetic patients with diabetic nephropathy completed this double-masked randomised crossover trial consisting of an initial washout period followed by three treatment periods each lasting 2 months, where all patients received lisinopril 20, 40 and 60 mg once daily in randomised order in addition to slow-release furosemide. Allocation was concealed by sequentially numbered opaque sealed envelopes. UAER, 24 h ambulatory blood pressure (ABP) and estimated GFR were determined at baseline and after each treatment period.All 49 patients completed all three treatment periods. Baseline values were: UAER (geometric mean [95

作者：K J, Schjoedt；A S, Astrup；F, Persson；E, Frandsen；F, Boomsma；K, Rossing；L, Tarnow；P, Rossing；H-H, Parving

来源：Diabetologia 2009 年 52卷 1期